Tag: typhoid vi polysaccharide vaccine market data

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Has the Typhoid Vi Polysaccharide Vaccine Market Size Changed, over the years?

The market size for the typhoid vi polysaccharide vaccine has seen a swift expansion in the past few years. Its growth is projected to accelerate from $5.78 billion in 2024 to $6.77 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 17.1%. Various factors driving the growth during the historic period include disease prevalence, global health initiatives, traveler vaccinations, governmental vaccination drives, as well as the effectiveness and safety of the vaccine.

How Much Will the Typhoid Vi Polysaccharide Vaccine Market Be Worth in 2029?

Expectations are high for the typhoid vi polysaccharide vaccine market to experience significant growth in the coming years, with projections estimating that it will reach $13.36 billion by 2029, growing at a compound annual growth rate (CAGR) of 18.5%. The predicted growth during the forecast period can be attributed to factors such as increased immunization initiatives, a growing focus on global health policies, epidemiological monitoring, a rise in demand within the field of travel medicine, as well as environmental and societal factors. Looking ahead, R&D investments, regulatory backing, epidemiological research, and public health awareness are key trends expected to shape the forecast period.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=8313&type=smp

Which is the Largest Company in the Typhoid Vi Polysaccharide Vaccine Market?

Major companies operating in the typhoid vi polysaccharide vaccine market are Sanofi S.A., GlaxoSmithKline PLC, Merck & Co. Inc., Pfizer Inc., Johnson & Johnson Private Limited, AstraZeneca PLC, Takeda Pharmaceutical Company Limited, Sun Pharmaceutical Industries Ltd., Mallinckrodt Pharmaceuticals, Emergent Biosolutions Inc., PT Bio Farma, Bharat Biotech International Limited, Teva Pharmaceutical Industries Ltd., Novartis AG, Bio-Med Pvt. Ltd., LG Chem, SK Chemicals Co. Ltd., Crucell Switzerland AG, Hualan Biological Engineering Inc., Indian Immunologicals Limited

What Are the Main Market Drivers in the Typhoid Vi Polysaccharide Vaccine Industry?

The escalating occurrence of typhoid is anticipated to fuel the expansion of the typhoid VI polysaccharide vaccine market. Typhoid, a potentially fatal disease, is brought on by the bacteria Salmonella typhi and is typically spread via infected beverages and food. The vaccine for Typhoid VI polysaccharide is utilized to protect both adults and children 2 years and over from typhoid fever, induced by Salmonella enterica serovar Typhi, S. Typhi. The UK Health Security Agency, a government establishment from the UK, shared data in August 2024 that proved a surge in the confirmed symptomatic cases of enteric fever in England, Wales, and Northern Ireland from 2021 to 2022. The figures showed that S. Typhi cases escalated from 108 to 313, S. Paratyphi A from 31 to 135, and S. Paratyphi B from 13 to 18 cases, respectively. As a result, the rising typhoid prevalence continues to drive the growth of the typhoid Vi polysaccharide vaccine market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=8313&type=smp

How Is the Typhoid Vi Polysaccharide Vaccine Market Segments Structured?

The typhoid vi polysaccharide vaccine market covered in this report is segmented –

1) By Type: Child, Adult

2) By Route Of Administration: Oral, Parenteral

3) By Application: Government Institution, Private Sector, Other Applications

Subsegments:

1) By Child: Pediatric Formulations, Age-Specific Dosages

2) By Adult: Standard Adult Formulations, High-Risk Population Formulations

What Strategic Trends Are Transforming the Typhoid Vi Polysaccharide Vaccine Market?

Key alliances are an emerging trend within the typhoid Vi polysaccharide vaccine market. Major players in this market are establishing partnerships that amplify their influence and solidify their standing in the market. For instance, in July 2022, the South Korea-based organization, The International Vaccine Institute, which focuses on infectious diseases of global significance like cholera, typhoid, shigella, and salmonella, formed a collaboration with Moderna, a biopharmaceutical firm based in the US. This collaboration resulted in the creation of the world’s first reasonably priced oral cholera vaccine and a new-generation typhoid conjugate vaccine.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/typhoid-vi-polysaccharide-vaccine-global-market-report

Which Global Regions Offer the Highest Growth in the Typhoid Vi Polysaccharide Vaccine Market?

Asia-Pacific was the largest region in the typhoid Vi polysaccharide vaccine market share in 2024. The regions covered in the typhoid vi polysaccharide vaccine market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=8313

This Report Delivers Insight On:

1. How big is the typhoid vi polysaccharide vaccine market, and how is it changing globally?

2. Who are the major companies in the typhoid vi polysaccharide vaccine market, and how are they performing?

3. What are the key opportunities and risks in the typhoid vi polysaccharide vaccine market right now?

4. Which products or customer segments are growing the most in the typhoid vi polysaccharide vaccine market?

5. What factors are helping or slowing down the growth of the typhoid vi polysaccharide vaccine market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Has the Typhoid Vi Polysaccharide Vaccine Market Size Changed, over the years?

The market size for the typhoid vi polysaccharide vaccine has seen a swift expansion in the past few years. Its growth is projected to accelerate from $5.78 billion in 2024 to $6.77 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 17.1%. Various factors driving the growth during the historic period include disease prevalence, global health initiatives, traveler vaccinations, governmental vaccination drives, as well as the effectiveness and safety of the vaccine.

How Much Will the Typhoid Vi Polysaccharide Vaccine Market Be Worth in 2029?

Expectations are high for the typhoid vi polysaccharide vaccine market to experience significant growth in the coming years, with projections estimating that it will reach $13.36 billion by 2029, growing at a compound annual growth rate (CAGR) of 18.5%. The predicted growth during the forecast period can be attributed to factors such as increased immunization initiatives, a growing focus on global health policies, epidemiological monitoring, a rise in demand within the field of travel medicine, as well as environmental and societal factors. Looking ahead, R&D investments, regulatory backing, epidemiological research, and public health awareness are key trends expected to shape the forecast period.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=8313&type=smp

Which is the Largest Company in the Typhoid Vi Polysaccharide Vaccine Market?

Major companies operating in the typhoid vi polysaccharide vaccine market are Sanofi S.A., GlaxoSmithKline PLC, Merck & Co. Inc., Pfizer Inc., Johnson & Johnson Private Limited, AstraZeneca PLC, Takeda Pharmaceutical Company Limited, Sun Pharmaceutical Industries Ltd., Mallinckrodt Pharmaceuticals, Emergent Biosolutions Inc., PT Bio Farma, Bharat Biotech International Limited, Teva Pharmaceutical Industries Ltd., Novartis AG, Bio-Med Pvt. Ltd., LG Chem, SK Chemicals Co. Ltd., Crucell Switzerland AG, Hualan Biological Engineering Inc., Indian Immunologicals Limited

What Are the Main Market Drivers in the Typhoid Vi Polysaccharide Vaccine Industry?

The escalating occurrence of typhoid is anticipated to fuel the expansion of the typhoid VI polysaccharide vaccine market. Typhoid, a potentially fatal disease, is brought on by the bacteria Salmonella typhi and is typically spread via infected beverages and food. The vaccine for Typhoid VI polysaccharide is utilized to protect both adults and children 2 years and over from typhoid fever, induced by Salmonella enterica serovar Typhi, S. Typhi. The UK Health Security Agency, a government establishment from the UK, shared data in August 2024 that proved a surge in the confirmed symptomatic cases of enteric fever in England, Wales, and Northern Ireland from 2021 to 2022. The figures showed that S. Typhi cases escalated from 108 to 313, S. Paratyphi A from 31 to 135, and S. Paratyphi B from 13 to 18 cases, respectively. As a result, the rising typhoid prevalence continues to drive the growth of the typhoid Vi polysaccharide vaccine market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=8313&type=smp

How Is the Typhoid Vi Polysaccharide Vaccine Market Segments Structured?

The typhoid vi polysaccharide vaccine market covered in this report is segmented –

1) By Type: Child, Adult

2) By Route Of Administration: Oral, Parenteral

3) By Application: Government Institution, Private Sector, Other Applications

Subsegments:

1) By Child: Pediatric Formulations, Age-Specific Dosages

2) By Adult: Standard Adult Formulations, High-Risk Population Formulations

What Strategic Trends Are Transforming the Typhoid Vi Polysaccharide Vaccine Market?

Key alliances are an emerging trend within the typhoid Vi polysaccharide vaccine market. Major players in this market are establishing partnerships that amplify their influence and solidify their standing in the market. For instance, in July 2022, the South Korea-based organization, The International Vaccine Institute, which focuses on infectious diseases of global significance like cholera, typhoid, shigella, and salmonella, formed a collaboration with Moderna, a biopharmaceutical firm based in the US. This collaboration resulted in the creation of the world’s first reasonably priced oral cholera vaccine and a new-generation typhoid conjugate vaccine.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/typhoid-vi-polysaccharide-vaccine-global-market-report

Which Global Regions Offer the Highest Growth in the Typhoid Vi Polysaccharide Vaccine Market?

Asia-Pacific was the largest region in the typhoid Vi polysaccharide vaccine market share in 2024. The regions covered in the typhoid vi polysaccharide vaccine market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=8313

This Report Delivers Insight On:

1. How big is the typhoid vi polysaccharide vaccine market, and how is it changing globally?

2. Who are the major companies in the typhoid vi polysaccharide vaccine market, and how are they performing?

3. What are the key opportunities and risks in the typhoid vi polysaccharide vaccine market right now?

4. Which products or customer segments are growing the most in the typhoid vi polysaccharide vaccine market?

5. What factors are helping or slowing down the growth of the typhoid vi polysaccharide vaccine market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Has the Typhoid Vi Polysaccharide Vaccine Market Size Changed, over the years?

The market size for the typhoid vi polysaccharide vaccine has seen a swift expansion in the past few years. Its growth is projected to accelerate from $5.78 billion in 2024 to $6.77 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 17.1%. Various factors driving the growth during the historic period include disease prevalence, global health initiatives, traveler vaccinations, governmental vaccination drives, as well as the effectiveness and safety of the vaccine.

How Much Will the Typhoid Vi Polysaccharide Vaccine Market Be Worth in 2029?

Expectations are high for the typhoid vi polysaccharide vaccine market to experience significant growth in the coming years, with projections estimating that it will reach $13.36 billion by 2029, growing at a compound annual growth rate (CAGR) of 18.5%. The predicted growth during the forecast period can be attributed to factors such as increased immunization initiatives, a growing focus on global health policies, epidemiological monitoring, a rise in demand within the field of travel medicine, as well as environmental and societal factors. Looking ahead, R&D investments, regulatory backing, epidemiological research, and public health awareness are key trends expected to shape the forecast period.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=8313&type=smp

Which is the Largest Company in the Typhoid Vi Polysaccharide Vaccine Market?

Major companies operating in the typhoid vi polysaccharide vaccine market are Sanofi S.A., GlaxoSmithKline PLC, Merck & Co. Inc., Pfizer Inc., Johnson & Johnson Private Limited, AstraZeneca PLC, Takeda Pharmaceutical Company Limited, Sun Pharmaceutical Industries Ltd., Mallinckrodt Pharmaceuticals, Emergent Biosolutions Inc., PT Bio Farma, Bharat Biotech International Limited, Teva Pharmaceutical Industries Ltd., Novartis AG, Bio-Med Pvt. Ltd., LG Chem, SK Chemicals Co. Ltd., Crucell Switzerland AG, Hualan Biological Engineering Inc., Indian Immunologicals Limited

What Are the Main Market Drivers in the Typhoid Vi Polysaccharide Vaccine Industry?

The escalating occurrence of typhoid is anticipated to fuel the expansion of the typhoid VI polysaccharide vaccine market. Typhoid, a potentially fatal disease, is brought on by the bacteria Salmonella typhi and is typically spread via infected beverages and food. The vaccine for Typhoid VI polysaccharide is utilized to protect both adults and children 2 years and over from typhoid fever, induced by Salmonella enterica serovar Typhi, S. Typhi. The UK Health Security Agency, a government establishment from the UK, shared data in August 2024 that proved a surge in the confirmed symptomatic cases of enteric fever in England, Wales, and Northern Ireland from 2021 to 2022. The figures showed that S. Typhi cases escalated from 108 to 313, S. Paratyphi A from 31 to 135, and S. Paratyphi B from 13 to 18 cases, respectively. As a result, the rising typhoid prevalence continues to drive the growth of the typhoid Vi polysaccharide vaccine market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=8313&type=smp

How Is the Typhoid Vi Polysaccharide Vaccine Market Segments Structured?

The typhoid vi polysaccharide vaccine market covered in this report is segmented –

1) By Type: Child, Adult

2) By Route Of Administration: Oral, Parenteral

3) By Application: Government Institution, Private Sector, Other Applications

Subsegments:

1) By Child: Pediatric Formulations, Age-Specific Dosages

2) By Adult: Standard Adult Formulations, High-Risk Population Formulations

What Strategic Trends Are Transforming the Typhoid Vi Polysaccharide Vaccine Market?

Key alliances are an emerging trend within the typhoid Vi polysaccharide vaccine market. Major players in this market are establishing partnerships that amplify their influence and solidify their standing in the market. For instance, in July 2022, the South Korea-based organization, The International Vaccine Institute, which focuses on infectious diseases of global significance like cholera, typhoid, shigella, and salmonella, formed a collaboration with Moderna, a biopharmaceutical firm based in the US. This collaboration resulted in the creation of the world’s first reasonably priced oral cholera vaccine and a new-generation typhoid conjugate vaccine.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/typhoid-vi-polysaccharide-vaccine-global-market-report

Which Global Regions Offer the Highest Growth in the Typhoid Vi Polysaccharide Vaccine Market?

Asia-Pacific was the largest region in the typhoid Vi polysaccharide vaccine market share in 2024. The regions covered in the typhoid vi polysaccharide vaccine market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=8313

This Report Delivers Insight On:

1. How big is the typhoid vi polysaccharide vaccine market, and how is it changing globally?

2. Who are the major companies in the typhoid vi polysaccharide vaccine market, and how are they performing?

3. What are the key opportunities and risks in the typhoid vi polysaccharide vaccine market right now?

4. Which products or customer segments are growing the most in the typhoid vi polysaccharide vaccine market?

5. What factors are helping or slowing down the growth of the typhoid vi polysaccharide vaccine market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

2025 Market Reports Update: Market Size Forecasts to 2034, Key Trends, Leading Players, and Top Regions – Get Ahead of the Competition Today!

How Are Key Drivers in the Industry Acting as Catalysts for the Growth of theTyphoid Vi Polysaccharide Vaccine Market?

The escalating occurrence of typhoid is projected to fuel the expansion of the typhoid VI polysaccharide vaccine market in the future. Typhoid, a potentially deadly infection, is brought on by the bacterium Salmonella typhi and primarily spreads via contaminated food or drink. The vaccine against typhoid Vi polysaccharide is utilized to protect children over the age of 2 and adults from typhoid fever induced by Salmonella enterica serovar Typhi, or S. Typhi. For example, in August 2024, the UK Health Security Agency, a government entity, published data indicating that laboratory-confirmed symptomatic cases of enteric fever in England, Wales and Northern Ireland saw an uptick from 2021 to 2022, with occurrences of S. Typhi increasing from 108 to 313, S. Paratyphi A from 31 to 135, and S. Paratyphi B from 13 to 18. As such, the growing prevalence of typhoid is spurring on the typhoid Vi polysaccharide vaccine market’s growth.

Get Your Free Sample Report Now – Explore Exclusive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=8313&type=smp

#What Long-Term Growth Rate is Expected for theTyphoid Vi Polysaccharide Vaccine Market Between 2025 and 2034?

In recent times, the market for typhoid vi polysaccharide vaccine has experienced swift expansion. From 2024 to 2025, there would be a significant increase in its value from $5.78 billion to $6.77 billion, showing a compound annual growth rate (CAGR) of 17.1%. The noteworthy growth during the historical period can be credited to factors such as the prevalence of the disease, international health campaigns, vaccination of travelers, governmental efforts towards immunisation, and the efficacy and safety of the vaccine.

In the forthcoming years, the market size of the typhoid vi polysaccharide vaccine is projected to experience swift expansion. By 2029, its valuation is set to reach $13.36 billion, with a compound annual growth rate (CAGR) of 18.5%. The projected growth during the prediction period is predominantly due to the enhancement of immunization initiatives, focus on global health policies, epidemiological surveillance, an increase in demand within travel medicine, and environmental and societal factors. The forecast period also signifies significant trends including investment in research and development, regulatory support, epidemiological research, and public health awareness.

You can Directly Purchase the Report Here:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=8313

What Are the Current Market Growth and Trends in theTyphoid Vi Polysaccharide Vaccine Market That Industry Players Should Watch?

There is an increasing trend in the typhoid Vi polysaccharide vaccine market towards strategic collaborations. In order to secure their positioning within the sector, major firms are establishing partnerships with others. For instance, in July 2022, The International Vaccine Institute from South Korea, dedicated to fighting globally significant infectious diseases such as cholera, typhoid, shigella, and salmonella, formed a partnership with US-based biopharmaceutical corporation Moderna. This collaboration resulted in the creation of a cost-effective oral cholera vaccine and a new-generation typhoid conjugate vaccine, representing a world first.

What Are the Major Market Players Making an Impact on theTyphoid Vi Polysaccharide Vaccine Market Growth?

Major companies operating in the typhoid vi polysaccharide vaccine market are Sanofi S.A., GlaxoSmithKline PLC, Merck & Co. Inc., Pfizer Inc., Johnson & Johnson Private Limited, AstraZeneca PLC, Takeda Pharmaceutical Company Limited, Sun Pharmaceutical Industries Ltd., Mallinckrodt Pharmaceuticals, Emergent Biosolutions Inc., PT Bio Farma, Bharat Biotech International Limited, Teva Pharmaceutical Industries Ltd., Novartis AG, Bio-Med Pvt. Ltd., LG Chem, SK Chemicals Co. Ltd., Crucell Switzerland AG, Hualan Biological Engineering Inc., Indian Immunologicals Limited

Order Your Report Now For A Swift Delivery:

https://www.thebusinessresearchcompany.com/report/typhoid-vi-polysaccharide-vaccine-global-market-report

How Are the Key Segments of the Typhoid Vi Polysaccharide Vaccine Market Driving Opportunities and Innovations?

The typhoid vi polysaccharide vaccine market covered in this report is segmented –

1) By Type: Child, Adult

2) By Route Of Administration: Oral, Parenteral

3) By Application: Government Institution, Private Sector, Other Applications

Subsegments:

1) By Child: Pediatric Formulations, Age-Specific Dosages

2) By Adult: Standard Adult Formulations, High-Risk Population Formulations

Gain Exclusive Market Insights—Customize Your Research Report Today for Fast Delivery!

https://www.thebusinessresearchcompany.com/customise?id=8313&type=smpGlobal Typhoid Vi Polysaccharide Vaccine Market, Global Typhoid Vi Polysaccharide Vaccine Market Report, Global Typhoid Vi Polysaccharide Vaccine Market Trends, Global Typhoid Vi Polysaccharide Vaccine Market Size

Browse Through More Reports Similar to the Gobal Typhoid Vi Polysaccharide Vaccine Maret 2025, By The Business Research Company:

Pediatric Vaccine Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/pediatric-vaccine-global-market-report

DTP Vaccines Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/dtp-vaccine-global-market-report

Veterinary Vaccines Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/veterinary-vaccines-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on:

Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

How has the typhoid vi polysaccharide vaccine market size evolved in recent years?

The market size for the typhoid vi polysaccharide vaccine has seen a swift expansion in recent years. It’s projected to rise from $5.78 billion in 2024 to $6.77 billion in 2025, exhibiting a compound annual growth rate of 17.1%. Several factors have contributed to this growth in the historical period, including the prevalence of disease, worldwide health initiatives, vaccination among travelers, government-driven immunization drives, and the effectiveness and safety of the vaccine.

What are the predictions for the typhoid vi polysaccharide vaccine market size in the coming years?

The market for the typhoid vi polysaccharide vaccine is projected to experience swift expansion in the coming years, reaching a valuation of $13.36 billion by 2029 with a compound annual growth rate (CAGR) of 18.5%. The forecasted growth can be linked to widened vaccine programs, the emphasis on global health policies, vigilant epidemiological observation, a surge in travel medicine requirement and socio-environmental factors. The prediction period also reveals prominent trends such as investments in research and development, regulatory backing, epidemiological research, and heightened public health consciousness.

Get your typhoid vi polysaccharide vaccine market report here!

https://www.thebusinessresearchcompany.com/report/typhoid-vi-polysaccharide-vaccine-global-market-report

What key factors are fueling the growth of the typhoid vi polysaccharide vaccine market?

The increase in typhoid cases is anticipated to fuel the expansion of the typhoid VI polysaccharide vaccine market. Typhoid, a potentially deadly infection caused by the bacteria Salmonella typhi, typically spreads via contaminated food or beverages. The typhoid Vi polysaccharide vaccine is employed to inoculate adults and children who are at least 2 years old against typhoid fever triggered by Salmonella enterica serovar Typhi, otherwise known as S. Typhi. For instance, data published by the UK Health Security Agency in August 2024 indicated a spike in laboratory-confirmed symptomatic cases of enteric fever in England, Wales, and Northern Ireland between 2021 to 2022. Specifically, there was an increase in S. Typhi cases from 108 to 313, S. Paratyphi A from 31 to 135, and S. Paratyphi B from 13 to 18. Consequently, the surge in typhoid incidents is stimulating the expansion of the typhoid Vi polysaccharide vaccine market.

How is the global typhoid vi polysaccharide vaccine market divided into key segments?

The typhoid vi polysaccharide vaccine market covered in this report is segmented –

1) By Type: Child, Adult

2) By Route Of Administration: Oral, Parenteral

3) By Application: Government Institution, Private Sector, Other Applications

Subsegments:

1) By Child: Pediatric Formulations, Age-Specific Dosages

2) By Adult: Standard Adult Formulations, High-Risk Population Formulations

Get your free sample now – explore exclusive market insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=8313&type=smp

Who are the key firms paving the way for growth in the typhoid vi polysaccharide vaccine market?

Major companies operating in the typhoid vi polysaccharide vaccine market are Sanofi S.A., GlaxoSmithKline PLC, Merck & Co. Inc., Pfizer Inc., Johnson & Johnson Private Limited, AstraZeneca PLC, Takeda Pharmaceutical Company Limited, Sun Pharmaceutical Industries Ltd., Mallinckrodt Pharmaceuticals, Emergent Biosolutions Inc., PT Bio Farma, Bharat Biotech International Limited, Teva Pharmaceutical Industries Ltd., Novartis AG, Bio-Med Pvt. Ltd., LG Chem, SK Chemicals Co. Ltd., Crucell Switzerland AG, Hualan Biological Engineering Inc., Indian Immunologicals Limited

Which trends are expected to transform the typhoid vi polysaccharide vaccine market?

Forming strategic alliances is becoming a notable trend in the typhoid Vi polysaccharide vaccine marketplace. Many leading players in this sector are forging partnerships to reinforce their standing in the typhoid Vi polysaccharide vaccine landscape. For example, in July 2022, The International Vaccine Institute, an organization based in South Korea that specializes in tackling infectious diseases with significant global health impact such as cholera, typhoid, shigella, and salmonella, collaborated with Moderna, an American biopharmacology corporation. This collaboration resulted in the production of the world’s first cost-effective orally administered cholera vaccine and a revolutionary typhoid conjugate vaccine.

Unlock exclusive market insights – purchase your research report now for a swift delivery!

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=8313

What regions are contributing significantly to the growth of the typhoid vi polysaccharide vaccine market?

Asia-Pacific was the largest region in the typhoid Vi polysaccharide vaccine market share in 2024. The regions covered in the typhoid vi polysaccharide vaccine market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Browse Through More Similar Reports By The Business Research Company:

Pediatric Vaccine Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/pediatric-vaccine-global-market-report

DTP Vaccines Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/dtp-vaccine-global-market-report

Veterinary Vaccines Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/veterinary-vaccines-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on:

Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

What CAGR Will the Typhoid Vi Polysaccharide Vaccine Market Achieve During 2025–2034, and What Does It Indicate?

The market for the typhoid vi polysaccharide vaccine has witnessed a fast-paced expansion in the last few years. Its value is expected to climb from $5.78 billion in 2024 to $6.77 billion in 2025, reflecting a compound annual growth rate (CAGR) of 17.1%. Factors contributing to the growth in the historic period include the prevalence of the disease, worldwide health campaigns, vaccinations for travelers, government-led immunization programs, and the vaccine’s effectiveness and safety.

In the coming years, the market size for the typhoid vi polysaccharide vaccine is projected to experience a fast-paced expansion, surging to a whopping $13.36 billion by 2029, with a compound annual growth rate (CAGR) of 18.5%. The swelling growth during the forecast period can be linked to broadened vaccination initiatives, worldwide emphasis on healthcare policies, monitoring of disease patterns, elevated demand in the field of travel medicine and both environmental and societal influences. The key trends to look out for within this forecast period comprise of investments in research and development, regulatory backing, epidemiological research, and heightened public cognizance about health.

What Industry-Specific Factors Are Fueling the Growth of the typhoid vi polysaccharide vaccine Market?

The growth of the typhoid VI polysaccharide vaccine market is set to be fueled by an increasing prevalence of typhoid. Typhoid, a potentially deadly infection, is caused by the Salmonella typhi bacteria and is primarily spread through contaminated food and beverages. The typhoid Vi polysaccharide vaccine works to protect adults and children over the age of 2 from typhoid fever, which is provoked by the Salmonella enterica serovar Typhi, or S. Typhi. Data released by the UK Health Security Agency, a government organization based in the UK, in August 2024 suggests a rise in laboratory-confirmed symptomatic cases of enteric fever in England, Wales, and Northern Ireland from 2021 to 2022. This includes an increase of S. Typhi cases from 108 to 313, S. Paratyphi A from 31 to 135, and S. Paratyphi B from 13 to 18. As a result of this increased prevalence of typhoid, the market for the typhoid Vi polysaccharide vaccine is flourishing.

Request Your Free Typhoid Vi Polysaccharide Vaccine Market Report Sample Now!

https://www.thebusinessresearchcompany.com/sample.aspx?id=8313&type=smp

Who Are the Key Firms Paving the Way for Growth in the Typhoid Vi Polysaccharide Vaccine Market?

Major companies operating in the typhoid vi polysaccharide vaccine market are:

• Sanofi S.A._x000D_

• GlaxoSmithKline PLC_x000D_

• Merck & Co. Inc._x000D_

• Pfizer Inc._x000D_

• Johnson & Johnson Private Limited_x000D_

What Are the Most Influential Trends Currently Shaping the Typhoid Vi Polysaccharide Vaccine Market?

The formation of strategic collaborations is a prominent trend that is increasingly emerging within the typhoid Vi polysaccharide vaccine market. To solidify their market standing, notable companies within the typhoid Vi polysaccharide vaccine arena are resorting to partnership strategies. For example, in July 2022, the International Vaccine Institute, assigned to combating globally significant infectious diseases like cholera, typhoid, shigella, and salmonella and based in South Korea, joined forces with Moderna, a biopharmaceutical firm from the US. This alliance resulted in the creation of the first cost-effective oral cholera vaccine and newly-developed typhoid conjugate vaccine.

Pre-order Your Report for Quick and Easy Delivery!

https://www.thebusinessresearchcompany.com/report/typhoid-vi-polysaccharide-vaccine-global-market-report

What Are the Major Segments of the Typhoid Vi Polysaccharide Vaccine Market and Their Role in Driving Growth?

The typhoid vi polysaccharide vaccine market covered in this report is segmented –

1) By Type: Child, Adult

2) By Route Of Administration: Oral, Parenteral

3) By Application: Government Institution, Private Sector, Other Applications

Subsegments:

1) By Child: Pediatric Formulations, Age-Specific Dosages

2) By Adult: Standard Adult Formulations, High-Risk Population Formulations

Which Regions Are Essential for the Growth of the Typhoid Vi Polysaccharide Vaccine Market?

Asia-Pacific was the largest region in the typhoid Vi polysaccharide vaccine market share in 2024. The regions covered in the typhoid vi polysaccharide vaccine market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

How Is the Scope and Reach of the Typhoid Vi Polysaccharide Vaccine Market Defined?

Typhoid VI polysaccharide vaccine refers to the recommendation of active immunization for people aged two and up, concerning the prevention of typhoid fever caused by Salmonella typhi.

Browse Through More Similar Reports By The Business Research Company:

Pediatric Vaccine Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/pediatric-vaccine-global-market-report

DTP Vaccines Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/dtp-vaccine-global-market-report

Veterinary Vaccines Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/veterinary-vaccines-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: